Axel REE Selects Woolrich as First Field Trial Site for Rare Earth ISR at Caladão

Axel REE (ASX:AXL) has announced the selection of the Woolrich deposit as the site for its inaugural field trial of in situ recovery (ISR) for rare earth elements at the Caladão project in Brazil. This marks a significant transition for the company, moving from laboratory-based metallurgical work to field-scale development. The decision to conduct the trial on a defined area of approximately 2 hectares aims to generate critical operating parameters necessary for the design of a wellfield and processing system. The announcement highlights a total rare earth oxide (TREO) grade of 464-486 parts per million (ppm) at the site, with a notable 42% of the soluble rare earths being magnet rare earth oxides. This development is framed as a step towards establishing a functioning ISR model, but it is essential to evaluate how this aligns with Axel REE's previous disclosures and the broader context of its operational strategy.

Historically, Axel REE has focused on exploration and laboratory testing, with the Woolrich deposit previously demonstrating promising metallurgical characteristics consistent with an ionic-adsorption clay system. The selection of Woolrich follows earlier magnesium sulphate leach tests that confirmed its suitability for ISR. However, the announcement does not provide a clear timeline for the field trial or subsequent phases, which raises questions about the company's execution capabilities. The previous reports indicated a focus on advancing the Caladão project, but the lack of specific milestones or timelines in this announcement could suggest a continuation of the pattern of vague commitments that have characterized some of Axel REE's prior communications.

Financially, Axel REE currently holds a market capitalization of AUD 6.5 million. The company has not disclosed recent financial results, which limits the ability to assess its cash position and funding runway. Given the capital-intensive nature of developing ISR projects, understanding the financial context is crucial. The announcement mentions assembling a multidisciplinary technical team and conducting hydrogeological assessments, which implies a need for substantial funding. Without clarity on its current financial health, it is challenging to ascertain whether Axel REE can adequately support the field trial and subsequent operational phases without risking dilution or financial distress.

In terms of valuation, Axel REE operates in a competitive landscape of rare earth element developers. Direct peers such as Ionic Rare Earths Limited (ASX:IXR) and Australian Rare Earths Limited (ASX:AR3) are also engaged in similar projects and have demonstrated varying degrees of progress in their respective ISR initiatives. For instance, Ionic Rare Earths has a market cap of approximately AUD 30 million and has reported more advanced stages in its development pipeline, suggesting that it may offer better value relative to Axel REE. Australian Rare Earths, with a market cap of around AUD 15 million, is also progressing with its projects, indicating that Axel REE may need to demonstrate significant advancements to justify its current valuation.

The announcement of the Woolrich site selection does present some genuine positives. The site has been chosen based on its favorable geological characteristics, including low-relief topography and a well-developed lateritic regolith profile, which could enhance the efficiency of the ISR process. Furthermore, the previous auger intercepts from the site, including 8 meters at 597 ppm TREO, indicate a potentially rich resource that could support the company's ambitions. However, the lack of a clear operational timeline and the need for further technical studies may temper enthusiasm among investors.

Looking ahead, the next expected catalyst for Axel REE will likely be the completion of column leach work at Core Resources, as well as the installation of the wellfield and initiation of magnesium sulphate injection. However, no specific timeline for these activities has been disclosed, which adds to the uncertainty surrounding the company's operational trajectory. The absence of a defined schedule for these critical steps could hinder investor confidence and raise concerns about the company's ability to execute its plans effectively.

In conclusion, while the announcement regarding the selection of Woolrich as the first ISR field trial site is a notable step for Axel REE, it must be viewed in the context of the company's historical performance and financial position. The lack of specific timelines and the need for substantial funding raise questions about the company's execution capabilities. Therefore, this announcement can be classified as moderate, as it does not significantly enhance the company's strategic position or operational outlook. The headline sentiment, while framed positively, does not fully reflect the underlying challenges and uncertainties facing Axel REE in the current market environment.

Key insights

• ●Woolrich site selection marks a shift to field-scale development.
• ●No specific timeline for field trial raises execution concerns.
• ●Axel REE's valuation appears weaker compared to peers.

Disagree with this article?